The third edition of the VHIOVida Festival, which was held on Saturday October 19, in Cabrils, brought together more than…
colorectal cancer
Dr. Mate Maus, head of the Aging and Cancer Group at VHIO, has been awarded the XXVIII FERO Grant for…
First results of two multi-center international Phase 1 dose-escalation and -expansion clinical trials of novel T-cell bispecific antibody cibisatamab as…
Checkmate 8HW is the first phase III study to assess first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch…
Chemotherapy resistance is often driven by cancer cells entering into a slow-cycling or dormant state to evade therapy-induced cell death….
VHIO has participated in this project coordinated by INCLIVA, which has made it possible to expand knowledge about this type…
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some…
The annual ASCO Symposium on Gastrointestinal Cancers took place from 19-21 January. Josep Tabernero, Director of VHIO, presented the results…
The multicenter randomized phase III BREAKWATER trial, spearheaded by VHIO, is the first to evaluate the combination of study drugs…
